Opportunity for those diagnosed with NASH and fibrosis to take part in the Boehringer Ingelheim 1404-0043 clinical research study

Posted on: 27th July 2022

Managing non-alcohol related steatohepatitis (NASH) and fibrosis currently relies entirely on lifestyle changes. Weight loss can be hard to achieve and maintain. That’s why Boehringer Ingelheim are conducting the 1404-0043 clinical research study – they want to find out whether an investigational medication could support weight loss and improve liver health in people with NASH and fibrosis.

They are looking for people to join the study, who, among other things:

Are between 18 and 80 years old (inclusive)
Have a diagnosis of NASH and fibrosis
Have a BMI of 25 kg/m2 or above and body weight of 70 kg or above

If you’re interested in taking part or would like more information about the study, please contact your nearest study site below quoting ‘1404-0043 NASH Boehringer study’:

  • Queen Elizabeth Hospital, Birmingham – Professor P Newsome . Please contact your GP and ask to be referred, quoting 1404-0043 NASH BI study, if you live within 60 miles of this site
  • Kings College Hospital, London – Dr K Agarwal. Please contact your GP and ask to be referred, quoting 1404-0043 NASH BI study
  • Aintree University Hospital, Liverpool – Dr C Sieberhagen. Please contact your GP and ask to be referred, quoting 1404-0043 NASH BI study, if you live within 25 miles of this site
  • Queens Medical Centre, Nottingham – Professor Ryder. If you live in the East Midlands, please email HEPGASTRORESEARCH@nuh.nhs.uk and ask to be referred, quoting 1404-0043 NASH BI study
  • Synexus, North East clinical Research Centre, Hexham – Dr Iyengar. Please call this number 0800 1615 001 quoting ‘113031051’, if you live within 50 miles of this site.
Back to News